NUREX - 2127 FLOW CYTOMETRY TESTING

[steve5441]

I just wanted to give a brief update on my latest flow test at MSK. Study sponsor, Nurex, wanted to take an extra tube of my blood this week to check for MRD. I've had two others of these in the past year while in the trial. My June 17, 2022 test showed Abnormal B Cell Population of 6.7% and Concentration of abnormal B Cells of 0.97 % . January 9th, 2023 test results, Abnormal B cell Population of 1.4 % and Concentration of 0.16 %. This is after my 15th cycle, or about 14 months. 100mg daily oral dosing. This trial always flys under the radar due to most of the attention aimed towards LOXO, which it should. Any of you numbers guys care to comment I would appreciate it.

[alpek]

Those results look great. Have you found the Nurex drug (degrader) to work slower similar to Ibrutinib/Pirtrobrutinib or more rapidly similar to Venetoclax? How have the side effects compared to the other medications you have been? Hopefully this agent becomes another line of therapy beyond btk/bcl2 inhibitors.

[steve5441 in reply to alpek]

I would say it's about the same as Ibrutinib and Loxo. I never had success with the Venetoclax. The worst side effects were from Ibrutinib, mostly heart and blood pressure issues, oh and bruising also. This Nurex 2127 really does a number on my ANC, I have to get a monthly injection of neulasta to keep my neutrophils in range. I would say for me, the Loxo-305 was the best of the previous oral treatment drugs. Good luck.

[Classicaljazz in reply to steve5441]

Thanks for posting your update and especially for comparing it with your past therapies - it is wonderful to get first-hand experience perspectives. I see that there are more than a dozen US sites currently recruiting for the NX-2127 Phase 1B clinical trial at clinicaltrials.gov/ct2/show...